Treatments in the Pipeline

Preventing it in the first place

The most decisive intervention is not treating SJS/TEN but avoiding it. Screening for specific HLA alleles before prescribing certain drugs already prevents cases — testing before abacavir is standard practice, and testing before carbamazepine in people of Southeast Asian ancestry is recommended on the drug label.

The research direction is toward broader pre-emptive pharmacogenomic panels embedded in prescribing systems, so the check happens automatically rather than depending on a clinician remembering. See Genetic Testing for where this stands today.

Modulating the acute immune reaction

SJS/TEN is driven by an immune attack on skin and mucosal cells, and several approaches aim to interrupt it early. Systemic corticosteroids, intravenous immunoglobulin, ciclosporin, and TNF-alpha inhibitors such as etanercept have all been used, and the evidence base for each remains genuinely contested — studies are small, the condition is rare, and randomising critically ill patients is difficult.

The honest summary is that supportive care in a burn center, and stopping the culprit drug immediately, remain the interventions with the least argument about them.

Protecting the eye during the acute phase

This is where the ophthalmology field has moved most clearly. Amniotic membrane transplantation — applying human amniotic membrane to the ocular surface as a biological dressing during the acute illness — is used to reduce scarring and later vision loss. Timing appears to matter a great deal: it is described as most effective when done within about a week of the rash starting, and considerably less so later.

This is the practical reason early ophthalmology involvement matters so much. The window for the intervention that most changes long-term vision closes while the patient is still acutely unwell.

Rebuilding a damaged surface

For survivors already living with corneal damage, work continues on limbal stem cell transplantation, cultivated epithelial grafts, and keratoprosthesis — an artificial cornea, used where conventional transplantation will not survive in a dry, scarred eye. Scleral devices such as PROSE remain the least invasive route to usable vision for many people and continue to improve.